Expands Breadth of Nimbus Drug Discovery Network

CAMBRIDGE, Mass. – November 8, 2012 – Nimbus Discovery LLC, today announced that it has executed a Privileged Partnership Agreement with Proteros Biostructures GmbH (“Proteros”), Martinsried, Germany. This partnership will accelerate drug discovery efforts against a growing pipeline of medically important targets.

Nimbus joins a select number of prestigious pharmaceutical and biotechnology companies that have entered into Privileged Partnership Agreements with Proteros. Privileged Partners are able to preferentially access Proteros’ new Gallery Structures, technologies and extensive in-house expertise to accelerate structure-based drug discovery efforts.

Jonathan Montagu, Vice President, Business Development and Operations at Nimbus commented, “Our cutting-edge computational platform relies heavily upon high quality x-ray structure data. Hence, our current collaboration with Proteros has been instrumental in our success with previously inaccessible targets. This expanded partnership is a logical progression of how we are integrating leading edge technologies to create a new model for drug discovery.”

Cony D’Cruz, Chief Business Officer and President, Proteros, US Inc. added, “We are excited to expand our collaboration with Nimbus. The relationship has been very productive and we look forward to continuing to support Nimbus’ innovative and proven discovery platform.”

About Nimbus

Nimbus Discovery, a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. We focus on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Our robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Nimbus is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors; including Atlas Venture, SR One, Lilly Ventures and Gates Ventures. For more information please visit www.nimbustx.com.

About Proteros biostructures GmbH

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America. For more information please visit www.proteros.com.

DOWNLOAD PRESS RELEASE